pcDNA3.3_SARS2_XBB Citations (2)

Originally described in: Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease.
Zhou P, Song G, Liu H, Yuan M, He WT, Beutler N, Zhu X, Tse LV, Martinez DR, Schafer A, Anzanello F, Yong P, Peng L, Dueker K, Musharrafieh R, Callaghan S, Capozzola T, Limbo O, Parren M, Garcia E, Rawlings SA, Smith DM, Nemazee D, Jardine JG, Safonova Y, Briney B, Rogers TF, Wilson IA, Baric RS, Gralinski LE, Burton DR, Andrabi R Immunity. 2023 Mar 14;56(3):669-686.e7. doi: 10.1016/j.immuni.2023.02.005. Epub 2023 Feb 16. PubMed Journal

---

Articles Citing pcDNA3.3_SARS2_XBB

Articles
Long-Term Dynamics of SARS-CoV-2 Variant-Specific Neutralizing Antibodies Following mRNA Vaccination and Infection. Vanova V, Nahlikova J, Lickova M, Slavikova M, Kajanova I, Lukacikova L, Sabo M, Radikova Z, Pastorekova S, Klempa B. Viruses. 2025 May 6;17(5):675. doi: 10.3390/v17050675. PubMed
High-Resolution Quantification of Two-Way Nanobody Synergy Using Automated Liquid Handling and Computational Modeling. Bourgeois NM, Bell SW, Olivier JP, Rout MP, Aitchison JD, Mast FD. Bio Protoc. 2026 Mar 5;16(5):e5615. doi: 10.21769/BioProtoc.5615. eCollection 2026 Mar 5. PubMed

If you have published an article using this material, please email us at to have your article added to this page.